Single Cell Discoveries has acquired TATAA Biocenter for an undisclosed amount. This corporate acquisition brings together TATAA Biocenter's specialized PCR bioanalytical services with Single Cell Discoveries. TATAA Biocenter operates as a Contract Research Organization (CRO), providing assay development, validation, and high-throughput analyses. Its services are crucial for nucleic acid therapy drug development, offering high sensitivity for regulated and non-regulated bioanalysis, clinical biomarkers, and manufacturing quality assessments. The company is GLP-accredited, GCLP-compliant, and ISO/IEC 17025-certified, emphasizing quality, innovation, and strong client relationships.
The acquisition is strategic, integrating TATAA Biocenter's deep expertise and robust operational framework into Single Cell Discoveries. TATAA Biocenter's purpose-built facility, designed for nucleic acid analyses, enhances sensitivity and minimizes contamination risks, representing a significant asset. Its state-of-the-art instrumentation and IT infrastructure ensure high data integrity and sample management, capabilities that will now extend to the acquiring entity. This move is set to expand Single Cell Discoveries' service portfolio, particularly in advanced bioanalytical testing and drug development support.
The combination of these entities is expected to yield operational efficiencies and broaden the scope of services available to clients. By integrating TATAA Biocenter's highly skilled scientists and precise execution with Single Cell Discoveries, the combined organization aims to offer a more comprehensive and specialized suite of bioanalytical solutions. This integration will allow for enhanced support for drug development pipelines, from early-stage research through to manufacturing quality control.
The unified entity is positioned to deliver greater value and expanded capabilities to its client base, strengthening its presence in the specialized bioanalytical and drug development services market.